FDA OKs Roche’s pTau217 Blood Test for Alzheimer’s Assessment

Roche has obtained U.S. Food and Drug Administration (FDA) clearance for its Elecsys Phospho-Tau (217P) Plasma blood test to aid in identifying Alzheimer’s-associated amyloid pathology in people 55 and older with signs of cognitive decline.

Developed with Eli Lilly, Elecsys pTau217 is reportedly the first and only FDA-cleared single-biomarker blood test designed to rule in or rule out amyloid pathology using validated clinical cutoffs across primary and specialty care. The test categorizes results as positive, intermediate, or negative to assess the likelihood of amyloid pathology, with findings interpreted alongside clinical information and other diagnostic data.

Elecsys pTau217 offers a minimally invasive option that fits existing clinical and laboratory workflows, helping assess amyloid pathology earlier and identify patients who may need further evaluation or specialist referral.

Following FDA clearance, the test may support clinical decision-making across primary and specialty care by providing positive, intermediate, or negative amyloid pathology results. The blood-based test may also help identify patients who need further evaluation and determine when additional testing, including PET imaging or CSF testing, may be appropriate.

In people 55 and older with signs of cognitive decline, Elecsys pTau217 showed high agreement with amyloid PET imaging, offering a minimally invasive option for assessing amyloid pathology. As a single-assay solution, it uses one biomarker and validated cutoffs to support both rule-in and rule-out assessment, an approach Roche calls the “Power of One.”

The test is designed for use on Roche’s over 4,500 cobas laboratory instruments in the U.S., leveraging existing infrastructure for broad access.

Comments from Roche, Eli Lilly, and clinicians

Dan Malarek, president and CEO, Roche Diagnostics North America: “FDA clearance of Elecsys pTau217 marks an important milestone in Alzheimer’s disease diagnosis and underscores Roche’s continued leadership in advancing innovative solutions that can help patients get answers sooner. As the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology, Elecsys pTau217 has the potential to transform how Alzheimer’s is assessed across primary and specialty care. This kind of innovation can help bring diagnostic evaluation closer to patients and give clinicians greater confidence in determining the right step in their care.”

Carole Ho, MD, executive VP and president, Lilly Neuroscience: “For millions of families navigating the uncertainty of Alzheimer’s disease, a timely diagnosis is the first and most critical step toward meaningful care. Lilly’s collaboration with Roche on Elecsys pTau217 was driven by a shared commitment to bringing one blood test into both primary care, where most patients with cognitive complaints are first seen, and specialty care, helping close the gap between symptoms and answers.”

Jared R. Brosch, MD, neurologist, Indiana University Health: “For decades, clinicians have faced significant challenges in accurately diagnosing Alzheimer’s disease in its early stages. While PET imaging and cerebrospinal fluid biomarkers can confirm amyloid pathology in patients with cognitive impairment, these approaches may be costly, invasive and not readily accessible for many patients. Advances in blood-based biomarkers have the potential to transform the diagnostic pathway by expanding access to evaluation for Alzheimer’s across a variety of care settings. As these tools become available, clinicians may be able to evaluate more patients earlier in the disease course, improving diagnostic confidence and helping patients and their families make more informed decisions at a critical time.”